Cure for the Common Cold!!!
LOS ANGELES, - The compound was tested in 300 asthmatic patients infected with the cold-causing human rhinovirus. The trial proved that cold symptoms eased quickly and the duration of the infection was shortened considerably.
Patients given a placebo went through the worst cold symptoms at 2.5 days. Patients dosed with Vapendavir began a speedy recovery after just 1.7 days.
Dr. Robert Stirling, from Melbourne's Alfred Hospital, reported that Vapendavir had the potential to "significantly impact the disabling symptoms of the rhinovirus bug.
"If this reduces the intensity and duration of a respiratory cold, especially in asthmatics, it is an important finding," he said.
"I think eventually we will be able to incorporate this treatment into our usual practice and we will find the economic benefits will outweigh health costs of treating infected patients. This could signal the death of the sickie," he said, using Australian slang for a sick day.
The cure will need to be tested in a bigger group of patients. In addition, Biota needs to satisfy regulators that it will fill an unmet need in healthcare before it is available to the public.
A double-blind, U.S. trial enrolled 300 asthmatic adults with symptomatic, naturally acquired HRV infection. The company said vapendavir appeared to be effective in all HRV species. The oral HRV antiviral was well tolerated with no serious adverse events reported. Biota said it plans to begin designing Phase III trials for vapendavir, but did not disclose a time frame for when the trials would start.
According to Smart Brief, "People with asthma who received Biota Holdings' oral antiviral drug candidate vapendavir experienced significant improvement in common cold symptoms, higher peak expiratory flow function, lower viral infection incidence and reduced need to take asthma relief drugs compared with the placebo group, a Phase IIb trial found. Biota is planning late-stage trials of vapendavir."
Patients given a placebo went through the worst cold symptoms at 2.5 days. Patients dosed with Vapendavir began a speedy recovery after just 1.7 days.
Dr. Robert Stirling, from Melbourne's Alfred Hospital, reported that Vapendavir had the potential to "significantly impact the disabling symptoms of the rhinovirus bug.
"If this reduces the intensity and duration of a respiratory cold, especially in asthmatics, it is an important finding," he said.
"I think eventually we will be able to incorporate this treatment into our usual practice and we will find the economic benefits will outweigh health costs of treating infected patients. This could signal the death of the sickie," he said, using Australian slang for a sick day.
The cure will need to be tested in a bigger group of patients. In addition, Biota needs to satisfy regulators that it will fill an unmet need in healthcare before it is available to the public.
A double-blind, U.S. trial enrolled 300 asthmatic adults with symptomatic, naturally acquired HRV infection. The company said vapendavir appeared to be effective in all HRV species. The oral HRV antiviral was well tolerated with no serious adverse events reported. Biota said it plans to begin designing Phase III trials for vapendavir, but did not disclose a time frame for when the trials would start.
According to Smart Brief, "People with asthma who received Biota Holdings' oral antiviral drug candidate vapendavir experienced significant improvement in common cold symptoms, higher peak expiratory flow function, lower viral infection incidence and reduced need to take asthma relief drugs compared with the placebo group, a Phase IIb trial found. Biota is planning late-stage trials of vapendavir."
Comment